文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

温经汤治疗韩国女性足部寒冷超敏反应的双盲随机对照试验方案

Efficacy and safety of Onkyeong-tang in treating cold hypersensitivity in the feet of Korean women: protocol for a double-blind, randomized, placebo-controlled, parallel-group, multicenter clinical study.
PubMed 文献 · Trials · 2020-05-18

本研究为双盲、随机、安慰剂对照、平行组、多中心预试验,计划纳入112名韩国女性足部寒冷超敏反应患者,按1:1随机分入温经汤组或安慰剂组,口服给药每日三次每次3g,持续8周。主要结局为足部寒冷超敏反应视觉模拟量表评分较基线的变化,次要结局包括手部寒冷超敏反应VAS评分、手足皮肤温度、WHO生活质量量表简版韩国版总分及冷应激试验结果。该试验旨在首次评估温经汤治疗足部寒冷超敏反应的有效性与安全性。

要点

  • 温经汤是临床常用治疗手足寒冷超敏反应的中药处方,但尚无随机临床试验评估其疗效与安全性。
  • 本试验为双盲、随机、安慰剂对照、平行组、多中心预试验,计划纳入112名韩国女性。
  • 主要结局为足部寒冷超敏反应VAS评分较基线的变化,给药方案为每日三次每次3g口服,持续8周。

核心结论

  • 本试验将首次评估温经汤治疗足部寒冷超敏反应的有效性与安全性,预期为温经汤的临床应用提供证据并为进一步大规模随机临床试验设计提供基础数据。

研究设计与样本

  • 双盲、随机、安慰剂对照、平行组、多中心预试验。
  • 计划纳入112名参与者,通过基于网络的随机化系统按1:1比例随机分为温经汤治疗组或安慰剂组。
  • 温经汤组与安慰剂组均口服给药,每日三次,每次3g,餐前或两餐之间服用,持续8周。

关键数值与推荐

  • 主要结局为足部寒冷超敏反应视觉模拟量表评分较基线的变化。
  • 次要结局包括手部寒冷超敏反应VAS评分变化、手足皮肤温度变化、世界卫生组织生活质量量表简版韩国版总分及冷应激试验结果。
  • 试验注册于Clinical Research Information Service(CRIS),注册号KCT0003723,于2019年4月8日回顾性注册。

临床怎么用

  • 温经汤已在临床广泛用于治疗手足寒冷超敏反应,但本试验结果尚未报告,暂不能据此形成临床推荐。

局限性

  • 本试验为预试验,样本量112例,主要目的在于为后续大规模随机临床试验提供设计基础数据。
  • 试验为回顾性注册(2019年4月8日注册),注册时间晚于试验起始。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cold hypersensitivity in the hands and feet (CHHF) commonly affects Asian women, especially Korean women, and it negatively impacts the quality of life of the affected individuals. One commonly used herbal prescription for treating CHHF is Onkyeong-tang (OKT). Although OKT is widely used clinically in treating CHHF, no randomized clinical trial has been performed to evaluate the efficacy and safety of OKT in the treatment of cold hypersensitivity in the feet (CHF). This clinical trial aims to provide objective evidence for the basis of using OKT in the treatment of CHF in Korean women. METHODS: This trial will be a double-blind, randomized, placebo-controlled, parallel-group, multicenter pilot study. A total of 112 participants will be randomly divided into an OKT treatment group or a placebo group with a 1:1 ratio via a web-based randomization system. The OKT and placebo groups will receive prescribed medications orally three times per day (3 g each time) before or between meals for 8 weeks. The primary outcome studied will be the changes in Visual Analog Scale (VAS) scores of CHF from baseline. Secondary outcomes studied will be the VAS score changes of cold hypersensitivity in the hands, changes in the skin temperature of the hands and feet, total scores of the Korean version of the World Health Organization Quality of Life Scale-abbreviated version, and the results of the cold stress test. DISCUSSION: This trial will be the first clinical trial to assess the efficacy and safety of OKT in the treatment of CHF. We anticipate that the findings of the study will provide evidence for the basis of using OKT in treating CHF symptoms and generate basic data for designing a further large-scale randomized clinical trial. TRIAL REGISTRATION: Clinical Research Information Service (CRIS): KCT0003723. Retrospectively registered on 8 April 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lee KY, Han IS, Go HY, et al. Efficacy and safety of Onkyeong-tang in treating cold hypersensitivity in the feet of Korean women: protocol for a double-blind, randomized, placebo-controlled, parallel-group, multicenter clinical study. Trials. 2020. PMID: 32423429. doi:10.1186/s13063-020-04265-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。